Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Eligible patients with estrogen receptor positive breast cancer will undergo a biopsy and be
randomized to receive endocrine therapy (ET) versus endocrine therapy with palbociclib (PET)
in a 1:2 ratio. After 1 cycle (28 days) another biopsy will be obtained, and both arms will
receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
Allegheny Health Network National Institutes of Health (NIH) Pfizer